Bone News and Research RSS Feed - Bone News and Research

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy. [More]
SI-BONE wins Gold 2014 International MarCom Award for SI Joint Patient Community website

SI-BONE wins Gold 2014 International MarCom Award for SI Joint Patient Community website

SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, won the Gold 2014 International MarCom Award for its SI Joint Patient Community website and an Honorable Mention for the SI Buddy Patient Networking Program. [More]
Researchers report promising outcomes from clinical trial in patients with dyskeratosis congenita

Researchers report promising outcomes from clinical trial in patients with dyskeratosis congenita

Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center report promising outcomes from a clinical trial with patients with a rare form of bone marrow failure who received a hematopoietic stem cell transplant (HSCT) after pre-treatment with immunosuppressive drugs only. This is the first trial reporting successful transplant in dyskeratosis congenita (DC) patients without the use of any radiation or conventional cytotoxic chemotherapy beforehand. [More]
Subsets of cells drive spread of multiple myeloma

Subsets of cells drive spread of multiple myeloma

Although it is among the most highly metastatic of all cancers, multiple myeloma is driven to spread by only a subset of the myeloma cells within a patient's body, researchers at Dana-Farber Cancer Institute have found in a study presented at the annual meeting of the American Society of Hematology. [More]
Oral targeted drug shows encouraging activity in patients with relapsed or resistant AML

Oral targeted drug shows encouraging activity in patients with relapsed or resistant AML

An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML) - a poor-prognosis group with few options - report investigators from Dana-Farber Cancer Institute and M.D. Anderson Cancer Center. [More]
Two-drug combination may be effective for patients with higher-risk forms of MDS and AML

Two-drug combination may be effective for patients with higher-risk forms of MDS and AML

A phase two study that investigated the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia. [More]
AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

AbbVie presented during an oral presentation at the American Society of Hematology's 56th Annual Meeting new results from a Phase 2 study of investigational compound venetoclax (ABT-199/GDC-0199) in patients with acute myelogenous leukemia (AML). AML is an aggressive and deadly type of blood cancer, in which the body produces too many of a specific type of white blood cell (myeloblast), which can crowd out healthy blood cells. [More]
Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Emerging treatment approaches may reduce the burden of anemia associated with blood disorders by enhancing production of healthy red blood cells, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM). [More]
Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments that harness the body's own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
Jakafi receives expanded approval from FDA for use in treatment of polycythemia vera

Jakafi receives expanded approval from FDA for use in treatment of polycythemia vera

Diplomat Pharmacy, Inc., the nation's largest independent specialty pharmacy, announced that the U.S. Food and Drug Administration has approved an expanded indication of Jakafi (ruxolitinib). [More]
NIHR recognises research study that aims to develop simple saliva test for gum diseases

NIHR recognises research study that aims to develop simple saliva test for gum diseases

A research study at Plymouth University Peninsula School of Dentistry (UK) which aims to develop a simple saliva test for gum diseases, has been recognised by the National Institute of Health Research, which has included the study in its portfolio. [More]
New study examines efficacy of brace application for treatment of spinal compression fractures

New study examines efficacy of brace application for treatment of spinal compression fractures

Compression fractures in the spine due to osteoporosis, a common condition causing progressive bone loss and increased fracture risk, are especially common in older women. A new study appearing in the December 3rd issue of the Journal of Bone & Joint Surgery found that patients who wore a brace as treatment for a spinal compression fracture had comparable outcomes in terms of pain, function and healing when compared to patients who did not wear a brace. [More]
Landmark CoMMpass Study data now available through MMRF Researcher Gateway

Landmark CoMMpass Study data now available through MMRF Researcher Gateway

The Multiple Myeloma Research Foundation announced today that new data from the landmark CoMMpass Study is now available to researchers via the MMRF's Researcher Gateway, an online, open-access portal designed to make key genomic and clinical data publically available for additional study. [More]
Scientists seek to improve stem cell transplant outcomes using DNA sequencing, mathematical modeling

Scientists seek to improve stem cell transplant outcomes using DNA sequencing, mathematical modeling

Is the human immune system similar to the weather, a seemingly random yet dynamical system that can be modeled based on past conditions to predict future states? Scientists at VCU Massey Cancer Center's award-winning Bone Marrow Transplant (BMT) Program believe it is, and they recently published several studies that support the possibility of using next-generation DNA sequencing and mathematical modeling to not only understand the variability observed in clinical outcomes of stem cell transplantation, but also to provide a theoretical framework to make transplantation a possibility for more patients who do not have a related donor. [More]
BME announces launch of Speed Arc Nitinol Fixation System

BME announces launch of Speed Arc Nitinol Fixation System

BioMedical Enterprises announced the launch of the Speed Arc Nitinol Fixation System, the world's first superelastic shape memory fixation device that conforms to the sloping surface of the metaphyseal anatomy. This addition to the current patented BME Speed Fixation System is available in three different sizes to ensure a proper fit in varying patient anatomies. [More]
Alizé Pharma obtains exclusive worldwide rights to develop new therapy for bone diseases

Alizé Pharma obtains exclusive worldwide rights to develop new therapy for bone diseases

Alizé Pharma III SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, today announces that it has acquired exclusive worldwide rights to develop and commercialize a new family of peptides with bone anabolic properties. [More]
Organovo, Yale collaborate to develop bioprinted tissues for surgical transplantation research

Organovo, Yale collaborate to develop bioprinted tissues for surgical transplantation research

Organovo Holdings, Inc., a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, and Yale School of Medicine, Department of Surgery have formed a collaboration to develop bioprinted tissues for surgical transplantation research, made possible by a generous gift from the Methuselah Foundation. [More]
Study explores use of bisphosphonates for men receiving androgen deprivation therapy

Study explores use of bisphosphonates for men receiving androgen deprivation therapy

Although some guidelines recommend use of bisphosphonates (a class of drugs used to strengthen bone) for men on androgen deprivation therapy, an analysis finds that prescriptions for these drugs remains low, even for those men at high risk of subsequent fractures, according to a study in the December 3 issue of JAMA. [More]